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Background
Infection with herpes simplex virus type 2 (HSV-2) is associated with an increased 
risk of acquiring infection with the human immunodeficiency virus (HIV). This study 
tested the hypothesis that HSV-2 suppressive therapy reduces the risk of HIV acqui-
sition.
Methods
Female workers at recreational facilities in northwestern Tanzania who were 16 to 
35 years of age were interviewed and underwent serologic testing for HIV and HSV-2. 
We enrolled female workers who were HIV-seronegative and HSV-2–seropositive in 
a randomized, double-blind, placebo-controlled trial of suppressive treatment with 
acyclovir (400 mg twice daily). Participants attended mobile clinics every 3 months 
for a follow-up period of 12 to 30 months, depending on enrollment date. The pri-
mary outcome was the incidence of infection with HIV. We used a modified inten-
tion-to-treat analysis; data for participants who became pregnant were censored. 
Adherence to treatment was estimated by a tablet count at each visit.
Results
A total of 821 participants were randomly assigned to receive acyclovir (400 partici-
pants) or placebo (421 participants); 679 (83%) completed follow-up. Mean follow-up 
for the acyclovir and placebo groups was 1.52 and 1.62 years, respectively. The in-
cidence of HIV infection was 4.27 per 100 person-years (27 participants in the acyclo-
vir group and 28 in the placebo group), and there was no overall effect of acyclovir 
on the incidence of HIV (rate ratio for the acyclovir group, 1.08; 95% confidence in-
terval, 0.64 to 1.83). The estimated median adherence was 90%. Genital HSV was 
detected in a similar proportion of participants in the two study groups at 6, 12, and 
24 months. No serious adverse events were attributable to treatment with acyclovir.
Conclusions
These data show no evidence that acyclovir (400 mg twice daily) as HSV suppressive 
therapy decreases the incidence of infection with HIV. (Current Controlled Trials 
number, ISRCTN35385041.)
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New strategies for the prevention of infection with the human immunode-ficiency virus (HIV) are needed, especially 
in sub-Saharan Africa. The prevalence of HIV in-
fection in people 15 to 49 years of age in Tanzania 
is estimated at 6.5%,1 and it reaches 40% in high-
risk groups such as workers in bars and guest-
houses,2-4 who may supplement their income by 
offering sex in return for money or gifts. The use 
of condoms with clients remains low among these 
workers, despite intensive educational campaigns,5 
and sexually transmitted infections are highly 
prevalent, especially infection with the herpes sim-
plex virus type 2 (HSV-2), with a prevalence of up 
to 80%.2,4,6 Observational studies suggest that 
HSV-2 infection doubles or triples the risk of ac-
quiring HIV and may contribute to more than 
50% of HIV infections in sub-Saharan Africa.7,8 
In Tanzania, an estimated 74% of new HIV infec-
tions in men, 22% in women, and 63% in bar and 
hotel workers are attributable to HSV-2.9,10 HSV-2 
may also be important in the transmission of HIV, 
and recent randomized, controlled trials of her-
pes suppressive therapy in HIV-positive subjects 
have demonstrated reductions in genital and plas-
ma HIV viral load over a 3-month period.11-14
Here we report the results of a randomized, 
controlled trial to test the hypothesis that herpes 
suppressive therapy might reduce HIV acquisition. 
The primary objective of this trial was to deter-
mine whether a standard suppressive regimen of 
acyclovir would reduce the incidence of infection 
with HIV in an occupational cohort of females in 
which a high proportion of HIV infections may 
be attributable to HSV-2.
Me thods
Participants
Females 16 to 35 years of age in 19 communities 
in northwestern Tanzania who worked in bars, 
guesthouses, and other food and recreational fa-
cilities were invited to attend mobile clinics and 
were screened for the presence of HSV-2 and HIV 
antibodies, as described previously.4 After screen-
ing, they were invited to return to the clinic ap-
proximately 8 to 12 weeks later. To be eligible for 
enrollment, participants had to be HSV-2–seroposi-
tive, 16 to 35 years of age, not pregnant or plan-
ning a pregnancy in the next 2 years, and not breast-
feeding. They had to reside near a trial site, with 
no plans to move, and they had to be present at 
the site at the time of the next scheduled visit. 
Potential participants who had a seizure disorder 
or were too unwell to participate were excluded.
Informed consent was obtained in several 
stages. Group and individual discussions about 
the trial were held during orientation activities 
and screening. At enrollment, participants received 
informational leaflets along with a picture book 
and an audiocassette tape explaining the aims and 
procedures of the trial. An eight-question com-
prehension check was performed; if the key con-
cepts were not understood, they were explained 
and the questions were asked again. Participants 
unable to understand the key concepts were not 
enrolled.
Trial Procedures
After participants had consented in writing or by 
fingerprint, blood and urine samples were ob-
tained and the urine sample was tested for preg-
nancy. Participants were asked about their recent 
sexual behavior and symptoms of sexually trans-
mitted infections. At examination, vaginal and 
cervical specimens were obtained, and a cervico-
vaginal lavage using 3 ml of phosphate-buffered 
saline was performed. Genital ulcers were swabbed. 
Participants were offered free family planning and 
syndromic management for sexually transmitted 
infections.
Participants were randomly assigned to receive 
either acyclovir (400 mg twice daily) or matching 
placebo, using randomly permuted blocks of four, 
and were given a 4-month supply of study tablets. 
Participants and the trial team remained un-
aware of the treatment allocation throughout 
the trial.
The mobile clinic team visited each site ap-
proximately every 12 weeks. At scheduled visits, 
participants were interviewed, a 10-ml blood 
sample was collected, tablets were counted, and 
additional tablets were issued. Participants were 
given counseling and advice on adherence. They 
were tested for pregnancy if their menstrual 
period was late or if they thought they might be 
pregnant; pregnant participants stopped taking 
the study tablets. Pregnant participants and par-
ticipants who wanted to stop taking the study 
tablets continued to receive all routine visit pro-
cedures except the provision of study tablets un-
less they asked to completely withdraw from the 
trial. Vaginal and cervical specimens were obtained 
and a cervicovaginal lavage was performed at 6, 
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12, 24, and 30 months; a genital examination was 
performed at other visits in participants who had 
symptoms. Participants received free treatment for 
minor medical conditions and were offered volun-
tary counseling and testing for HIV using rapid 
tests (Capillus HIV-1/HIV-2 assay [Trinity Biotech] 
and Abbott Determine assay [Abbott Laborato-
ries]) along with risk-reduction counseling and 
free condoms. At each visit, participants received 
3000 Tanzanian shillings (approximately $3) as 
reimbursement for their time.
Approximately 4 weeks after scheduled visits, 
a mobile adherence-support team visited partici-
pants to provide support and adherence counsel-
ing and to count remaining tablets. Between the 
6- and 9-month scheduled visits, a urine sample 
and data on the last study tablet taken were also 
obtained.
At 3, 9, 15, 21, and 27 months, participants 
were examined only if they had symptoms of a 
sexually transmitted infection, and they were given 
syndromic management or treatment of any un-
treated sexually transmitted infection identified 
by laboratory testing at their earlier visits. At base-
line and at 6, 12, 18, 24, and 30 months, par-
ticipants were examined and a blood sample was 
obtained; with the exception of the 18-month visit, 
vaginal and cervical samples were also obtained, 
a cervicovaginal lavage was performed, and par-
ticipants received syndromic treatment.
Adherence to treatment was estimated by tab-
let counts at each scheduled visit. Random sam-
ples of urine aliquots obtained by the adherence 
team and at the 6- and 24-month visits were fro-
zen at –20°C. These were tested for the presence 
of acyclovir by high-performance liquid chroma-
tography15 at an independent laboratory in the 
United Kingdom.
Participants who were HIV-positive at screen-
ing or who had undergone seroconversion during 
the trial and who chose to know their HIV status 
through voluntary counseling and testing were 
referred to HIV care and treatment centers. Free 
antiretroviral therapy became available in regional 
and district hospitals in the study area during 
the trial. At the end of the trial, funding was 
provided to allow HIV-positive participants to 
travel to their care and treatment center for the 
next 12 to 18 months. Participants who became 
pregnant during follow-up were referred to the 
nearest antenatal clinic.
Laboratory Methods
Serum samples obtained during screening were 
tested for HSV-2 using a type-specific IgG enzyme-
linked immunosorbent assay (ELISA) (Kalon Bio-
logicals). HIV testing of blood samples obtained 
at baseline and during follow-up was performed 
using the Murex HIV Ag/Ab Combination ELISA 
(Murex Biotech) and the Uni-Form II Ag/Ab mi-
cro ELISA system (bioMérieux BV). Samples with 
discordant or indeterminate results were retested. 
If results were not resolved on retesting, the sam-
ple was tested by HIV-1 p24 antigen enzyme im-
munoassay (Biorad Genetic Systems). If the result 
was positive, it was considered to be the final 
result. Samples with p24 antigen–negative or in-
determinate results and all samples from partici-
pants who had undergone seroconversion were 
tested by a line immunoassay (INNO-LIA HIV I/II, 
Innogenetics), and the results of the line immu-
noassay were taken as definitive. Participants were 
assessed for other genital tract infections includ-
ing syphilis, Trichomonas vaginalis, Chlamydia tra-
chomatis, and Neisseria gonorrhoeae; if ulcers were 
present, tests for HSV, syphilis, and Haemophilis 
ducreyi were performed (see the Supplementary 
Appendix, available with the full text of this ar-
ticle at www.nejm.org).
Statistical Analysis
The initial sample-size calculation assumed an 
HIV incidence of 10 per 100 person-years in the 
placebo group, with 80% power to detect a 50% 
reduction in HIV incidence, based on a two-sided 
type 1 error rate of 5%. Under this assumption, 
941 person-years of follow-up among HIV-nega-
tive participants was required, which was equiva-
lent to following 600 HIV-negative participants 
for 2 years, with a 15% loss of person-years over 
the 2-year period. The assumed incidence rate was 
based on results from a similar cohort in Mbeya, 
Tanzania.16 An independent data monitoring 
committee performed periodic reviews of adverse 
events and one interim analysis at 12 months, at 
which the committee noted that the pregnancy 
rate was higher and the incidence of infection 
with HIV lower than anticipated. There were no 
formal rules for stopping on the basis of efficacy 
or futility. Given the blinded HIV-incidence re-
sults at the interim analysis, the trial steering 
committee recommended that the sample size be 
increased to 821 and the follow-up period ex-
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tended to 30 months for 618 participants already 
enrolled (phases 1 and 2), with a 12-month fol-
low-up period for 203 newly enrolled participants 
(phase 3).
Data were double-entered and verified in 
Dbase-IV (dataBased Intelligence). Analyses were 
conducted with the use of Stata software, ver-
sion 10.0 (StataCorp). The analysis plan was fi-
nalized before completion of the trial and was 
approved by the data monitoring committee. For 
the primary modified intention-to-treat analy-
ses, participants were included until the earliest 
of the following points: the end of the follow-up 
period (30 months for those in phases 1 and 2 or 
12 months for those in phase 3), the date of the 
first positive pregnancy test, the date on which 
the participant was last seen, or the estimated date 
of HIV seroconversion, taken as the midpoint be-
tween the last negative and the first positive 
tests for HIV. Rates of HIV infection in the acy-
clovir and placebo groups were compared and 
unadjusted rate ratios were calculated, using Pois-
son regression. Logistic regression was used to 
assess the effect of treatment with acyclovir on 
detection of genital ulcers and cervicovaginal 
HSV DNA during follow-up.
Secondary analyses comprised an intention-
to-treat analysis; an on-treatment analysis, in 
which data for participants who stopped taking 
tablets for any reason were censored from the 
time of withdrawal; and a prespecified on-treat-
ment analysis stratified by estimated adherence 
within each 3-month period. If a participant did 
not bring back unused tablets or if she brought 
back too few tablets and reported that tablets had 
been lost, stolen, or damaged, adherence was 
classified as unknown. If a participant missed a 
visit, then adherence was calculated at her next 
visit and was based on the number of days that 
had elapsed since her last visit. A test for trend 
was used to assess whether the rate ratio for acy-
clovir versus placebo varied with reported adher-
ence. No subgroup analyses were performed.
The study protocol was approved by the Lon-
don School of Hygiene and Tropical Medicine 
ethics committee and by the Medical Research 
Coordinating Committee of Tanzania. Trial mon-
itoring was done by the United Kingdom Medi-
cal Research Council Clinical Trials Unit. Acy-
clovir and placebo tablets were purchased from 
Ranbaxy.
R esult s
A total of 2719 females were screened, and 821 
HIV-negative females were enrolled (421 in the 
placebo group and 400 in the acyclovir group) 
(Fig. 1) between January 2004 and May 2006. Par-
ticipant characteristics at baseline, including the 
prevalence of other infections of the reproductive 
tract, were similar in the two study groups (Table 
1). The median age was 28 years. Overall, 41% of 
participants reported having used a condom at 
last sexual intercourse, and 37% reported having 
had sex in exchange for money or gifts in the 
past 3 months (34% in the placebo group and 
40% in the acyclovir group). A history of genital 
ulceration or blisters was reported by 25% of par-
ticipants, and an ulcer or a blister was seen on 
examination in 2%.
Overall, 679 participants (83%) completed 
follow-up for the primary modified intention-to-
treat analysis, with similar follow-up time in both 
groups (1.52 years in the placebo group and 1.62 
years in the acyclovir group, P = 0.58 by the Wil-
coxon rank-sum test). For the primary analysis, 
data for 165 participants (20%) were censored be-
cause of pregnancy (19% in the placebo group and 
21% in the acyclovir group) (Fig. 1 and Table 2).
Effect of Acyclovir on HIV Incidence
For the primary modified intention-to-treat anal-
ysis (Table 3), there were 28 HIV seroconversions 
in the placebo group and 27 in the acyclovir 
group. The incidence of infection with HIV was 
4.12 per 100 person-years in the placebo group 
and 4.44 per 100 person-years in the acyclovir 
group. There was no evidence of an effect of 
treatment with acyclovir on the incidence of HIV 
infection (rate ratio, 1.08; 95% confidence inter-
val [CI], 0.64 to 1.83) (Fig. 2). The intention-to-
treat analysis showed similar results (rate ratio, 
1.01; 95% CI, 0.61 to 1.66), as did the on-treat-
ment analysis (rate ratio, 1.12; 95% CI, 0.66 to 
1.90). When the analysis was stratified by report-
ed adherence during each 3-month period of fol-
low-up, the estimated rate ratio for acyclovir was 
smaller than 1 for the high-adherence category 
and increased with lower adherence, but neither 
the trend nor any of the within-category rate ra-
tios were statistically significant. Reported ad-
herence was similar in the acyclovir and placebo 
groups, with at least 90% adherence reported 
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1385 Were eligible to undergo
randomization
2719 Females were screened
1334 Were not eligible
554 Were HSV-2–seronegative
13 Were HSV-2–indeterminate
751 Were HIV-1–seropositive
16 Were HIV-1–indeterminate 
821 Underwent randomization
564 Did not undergo randomization
317 Did not attend
17 Were HIV-seropositive
196 Were not eligible
34 Declined to participate
400 Were assigned to receive acyclovir 421 Were assigned to receive placebo
19 Were lost to follow-up
16 Were pregnant19 Were pregnant
26 Were lost to follow-up
374 Were included in the 3-mo follow-up 402 Were included in the 3-mo follow-up
8 Were lost to follow-up
11 Were pregnant9 Were pregnant
11 Were lost to follow-up
344 Were included in the 6-mo follow-up 378 Were included in the 6-mo follow-up
6 Were lost to follow-up
13 Were pregnant9 Were pregnant
11 Were lost to follow-up
324 Were included in the 9-mo follow-up 361 Were included in the 9-mo follow-up
8 Were lost to follow-up
7 Were pregnant
80 Ended follow-up
(phase 3)
75 Ended follow-up
(phase 3)
6 Were pregnant
4 Were lost to follow-up
311 Were included in the 12-mo follow-up 340 Were included in the 12-mo follow-up
5 Were lost to follow-up
6 Were pregnant9 Were pregnant
1 Was lost to follow-up
229 Were included in the 15-mo follow-up 248 Were included in the 15-mo follow-up
1 Was lost to follow-up
8 Were pregnant9 Were pregnant
4 Were lost to follow-up
3 Were lost to follow-up
216 Were included in the 18-mo follow-up 241 Were included in the 18-mo follow-up
5 Were lost to follow-up
1 Died
9 Were pregnant9 Were pregnant 204 Were included in the 21-mo follow-up 227 Were included in the 21-mo follow-up
1 Was lost to follow-up
9 Were pregnant
3 Refused to extend 
follow-up
10 Were pregnant
6 Refused to extend 
  follow-up
5 Were lost to follow-up
190 Were included in the 24-mo follow-up 217 Were included in the 24-mo follow-up
3 Were lost to follow-up
5 Were pregnant6 Were pregnant
3 Were lost to follow-up
171 Were included in the 27-mo follow-up 202 Were included in the 27-mo follow-up
8 Were lost to follow-up7 Were lost to follow-up
158 Were included in the 30-mo follow-up 189 Were included in the 30-mo follow-up
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Figure 1. Screening, Randomization, and Follow-up of Study Participants.
The New England Journal of Medicine 
Downloaded from nejm.org at LONDON SCH HYGIENE & TROPICAL MED on February 14, 2014. For personal use only. No other uses without permission. 
 Copyright © 2008 Massachusetts Medical Society. All rights reserved. 
Effect of HSV-2 Suppression on HIV Incidence
n engl j med 358;15 www.nejm.org ㄐㄐapril 10, 2008 1565
during 51% and 52% of person-years, respec-
tively.
In a total of 144 tested urine samples from 
participants in the acyclovir group, between 33% 
and 67% had evidence of acyclovir, as compared 
with 5% of 146 samples tested from those in the 
placebo group (Table 4).
Reported Sexual Behavior, Episodes of Genital 
Ulceration, and HSV Shedding during Follow-up
The proportion of visits at which participants re-
ported having had more than one sexual partner 
in the preceding 3 months was 25% in the pla-
cebo group and 28% in the acyclovir group (odds 
ratio, 1.17; 95% CI, 0.92 to 1.48). Participants in 
the placebo group were slightly less likely to re-
port having had sex in exchange for money or 
gifts than were those in the acyclovir group (24% 
vs. 27%; odds ratio for the acyclovir group, 1.15; 
95% CI, 0.91 to 1.45). Adjustment for these fac-
tors made little difference to the rate ratio for the 
acyclovir group (1.06; 95% CI, 0.62 to 1.79, ad-
justed for number of partners; and 1.05; 95% CI, 
0.62 to 1.79, adjusted for partners with exchange 
of money or gifts).
On examination at scheduled study visits, 
there were six episodes of genital ulceration or 
blisters in the placebo group as compared with 
nine episodes in the acyclovir group (odds ratio 
for the acyclovir group, 1.69; 95% CI, 0.61 to 
4.70). Among participants with such episodes, 
HSV was detected in three in the placebo group 
and in one in the acyclovir group.
In cervicovaginal lavage specimens analyzed 
from a random sample of 450 participants at 6, 
12, and 24 months, HSV DNA was detected in 
4.5% of samples in the placebo group and in 
4.3% of samples in the acyclovir group (odds ratio 
for the acyclovir group, 0.98; 95% CI, 0.50 to 1.91). 
A stronger effect was seen among participants 
with at least 90% adherence to treatment during 
the preceding 3-month period (4.9% for placebo 
vs. 3.1% for acyclovir; odds ratio for acyclovir, 
0.63; 95% CI, 0.25 to 1.57).
Adverse Events
Serious adverse events were documented in 86 
participants (10.5%; 42 in the placebo group and 
44 in the acyclovir group) (Table 5). The most 
common serious adverse event was hospitaliza-
tion, primarily for malaria. One participant in the 
placebo group died from a cause related to alco-
hol use, and one participant who had withdrawn 
from the acyclovir group died in childbirth. No 
serious adverse event was attributed to acyclovir.
Discussion
Biologic and epidemiologic studies have dem-
onstrated strong synergy between HSV-2 and 
HIV.8-10,17-20 It is therefore plausible that therapy 
to suppress HSV might reduce HIV acquisition. 
However, we found no significant effect of twice-
daily treatment with acyclovir on the incidence of 
HIV infection among the participants in our study.
Possible explanations for the lack of effect 
include chance, limited power to detect moderate 
effects, bias due to losses to follow-up, and sub-
optimal adherence to treatment, or the acyclovir 
regimen (400 mg twice daily) may not be potent 
enough to fully suppress HSV-2 at the cellular 
level, especially if any dose is delayed.
Participants lost to follow-up in both groups 
were more likely to be younger and to consume 
10 or more alcoholic drinks per week. Both of 
these were independent risk factors for HIV in-
fection during the trial (results not shown). It is 
therefore possible that the overall incidence of 
infection with HIV in the trial was underesti-
mated and that this bias may have been slightly 
greater in the acyclovir group. In this case, the 
true rate ratio would be slightly higher and the 
main qualitative conclusions of the study would 
be unchanged.
This was a proof-of-concept trial, and we 
chose a standard suppressive acyclovir treatment 
regimen that has been shown to have an effi-
cacy against HSV shedding similar to that of 
valacyclovir (500 mg twice daily).21 HSV-2 infec-
tion is characterized by frequent subclinical reac-
tivations as well as clinical episodes,22 and recent 
evidence shows that it acts at the cellular level to 
potentiate HIV target cells.23 We considered it 
theoretically possible that partial suppression of 
HSV-2 might have an effect on the risk of HIV 
acquisition. However, the short half-life and poor 
absorption of acyclovir may mean that plasma 
levels are not sufficient or are not maintained at 
a level high enough to switch off this cellular 
trigger, especially if adherence is suboptimal. In 
contrast, oral valacyclovir is more readily ab-
sorbed, has higher trough plasma acyclovir lev-
els, and leads to greater bioavailability of acyclo-
vir, with a half-life of 2.62 to 3.13 hours.24,25 
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Table 1. Baseline Characteristics of the Participants.
Characteristic
Acyclovir Group  
(N = 400)
Placebo Group  
(N = 421)
Total  
(N = 821)
Age — yr
Median 28 27 28
Interquartile range 23–32 23–31 23–32
Age — no. (%)
16–19 yr 25 (6) 25 (6) 50 (6)
20–24 yr 94 (24) 104 (25) 198 (24)
25–29 yr 113 (28) 137 (33) 250 (30)
30–35 yr 168 (42) 155 (37) 323 (39)
Marital status — no. (%)
Unmarried 78 (20) 87 (21) 165 (20)
Married or living as married 111 (28) 127 (30) 238 (29)
Divorced or separated 192 (48) 192 (46) 384 (47)
Widowed 19 (5) 15 (4) 34 (4)
Educational level — no. (%)
Less than primary 120 (30) 137 (33) 257 (31)
Primary 260 (65) 262 (62) 522 (64)
Secondary 20 (5) 22 (5) 42 (5)
Type of work or work facility — no. (%)
Local food handler 215 (54) 223 (53) 438 (53)
Guesthouse 44 (11) 47 (11) 91 (11)
Bar 48 (12) 55 (13) 103 (13)
Local brew seller 27 (7) 30 (7) 57 (7)
Restaurant, cafe, or grocery 66 (16) 66 (16) 132 (16)
Type of site — no. (%)
Trading center 102 (26) 118 (28) 220 (27)
Mining town 82 (20) 81 (19) 163 (20)
Truck stop 216 (54) 222 (53) 438 (53)
Travel in past 3 months — no. (%)
None 276 (69) 306 (73) 582 (71)
<1 wk total 28 (7) 29 (7) 57 (7)
≥1 trip lasting >1 wk 96 (24) 86 (20) 182 (22)
Number of sexual partners in past 3 mo — no. (%)
0 44 (11) 35 (8) 79 (10)
1 222 (56) 240 (57) 462 (56)
2–3 104 (26) 120 (29) 224 (27)
≥4 30 (8) 26 (6) 56 (7)
Sexual partners in lifetime — no. (%)
0–1 21 (5) 12 (3) 33 (4)
2–4 156 (39) 158 (38) 314 (38)
5–9 133 (33) 153 (36) 286 (35)
10–24 67 (17) 81 (19) 148 (18)
≥25 23 (6) 17 (4) 40 (5)
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Table 1. (Continued.)
Characteristic
Acyclovir Group  
(N = 400)
Placebo Group  
(N = 421)
Total  
(N = 821)
Sexual partners with whom sex was exchanged for 
gifts or money in past 3 mo — no. (%)
0 241 (60) 278 (66) 519 (63)
1 111 (28) 97 (23) 208 (25)
2–3 40 (10) 38 (9) 78 (10)
≥4 8 (2) 8 (2) 16 (2)
Condom use — no. (%)
Never 85 (21) 85 (20) 170 (21)
Sometimes 171 (43) 178 (42) 349 (43)
Often 73 (18) 67 (16) 140 (17)
Always 71 (18) 91 (22) 162 (20)
Condom use during most recent sexual act — no. (%)
No 164 (41) 173 (41) 337 (41)
Yes 236 (59) 248 (59) 484 (59)
Alcoholic drinks/wk — no. (%)
0 198 (50) 213 (51) 411 (50)
1–4 97 (24) 102 (24) 199 (24)
5–9 40 (10) 33 (8) 73 (9)
10–19 22 (6) 40 (10) 62 (8)
≥20 43 (11) 33 (8) 76 (9)
Medical injection within past 5 yr — no. (%)
No 92 (23) 124 (29) 216 (26)
Yes 308 (77) 297 (71) 605 (74)
Receipt of blood transfusion — no. (%)
Never 351 (88) 385 (92) 736 (90)
Ever 49 (12) 35 (8) 84 (10)
Neisseria gonorrhoeae infection — no. (%)
No 381 (95) 405 (96) 786 (96)
Yes 19 (5) 16 (4) 35 (4)
Chlamydia trachomatis infection — no. (%)
No 371 (93) 388 (92) 759 (92)
Yes 29 (7) 33 (8) 62 (8)
Active syphilis — no. (%)*
No 344 (86) 372 (88) 716 (87)
Yes 56 (14) 49 (12) 105 (13)
Bacterial vaginosis
No or intermediate 174 (44) 164 (39) 338 (41)
Yes 226 (57) 257 (61) 483 (59)
Trichomonas vaginalis infection — no. (%)
No 284 (71) 312 (74) 596 (73)
Yes 114 (29) 108 (26) 222 (27)
* Data for receipt of blood transfusion were missing for one participant in the placebo group and for Trichomonas vagina-
lis infection were missing for two participants in the acyclovir group and one participant in the placebo group. Active 
syphilis was defined by a positive rapid plasma reagin test and either a positive Treponema pallidum particle agglutina-
tion assay or a positive fluorescent treponemal antibody assay.
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Several trials of suppressive therapy with valacy-
clovir (500 mg twice daily) found significant re-
ductions in genital and plasma HIV over periods 
of up to 3 months.11-14 A trial of acyclovir (800 
mg twice daily) in Thailand found a significant 
effect on genital HIV viral load,26 and there was 
a significant reduction in plasma HIV and fre-
quency (but not quantity) of genital HIV in a trial 
of acyclovir (400 mg twice daily) in South Africa.12 
In contrast, no effect was found for this dose of 
acyclovir among HIV-positive participants in our 
trial.27 These results suggest that valacyclovir 
(500 mg twice daily) or a higher dose of acyclo-
vir may be necessary to reduce the replication of 
HSV-2 in populations in which adherence to treat-
ment is suboptimal.
The median adherence according to counting 
of tablets was 90%. Adherence proved challeng-
ing to measure. The main limitation of counting 
was that if participants did not bring back their 
tablet boxes, or if they reported that tablets had 
been lost, stolen, or damaged, an accurate esti-
mate of adherence was not possible. Even if 
participants did return their boxes, they could 
have discarded tablets before attending a visit. 
Because of these limitations, we also used a bio-
logic marker of adherence by testing for the pres-
ence of acyclovir in urine samples from a sample 
of participants. A substantial proportion of par-
ticipants in the acyclovir group did not have any 
acyclovir detectable, a finding that implies that 
it had been more than 12 hours since the par-
ticipants had taken a dose. We also found evi-
dence that a small number of participants in the 
placebo group had exchanged tablets with par-
ticipants in the acyclovir group, and this was 
most apparent soon after the start of the trial. 
However, one or two tablets of acyclovir taken by 
Table 2. Summary of Follow-up in the Two Study Groups.
Follow-up Status Acyclovir Group 
(N = 400)
Placebo Group 
(N = 421)
Modified intention-to-treat analysis — no. (%)
Completed follow-up 212 (53) 247 (59)
Was lost to follow-up 78 (20) 64 (15)
Became pregnant 83 (21) 82 (19)
Had HIV seroconversion 27 (7) 28 (7)
Intention-to-treat analysis — no. (%)
Completed follow-up 280 (70) 316 (75)
Was lost to follow-up 90 (23) 72 (17)
Had HIV seroconversion 30 (8) 33 (8)
On-treatment analysis — no. (%)
Completed follow-up 212 (53) 246 (58)
Was lost to follow-up 58 (14) 51 (12)
Became pregnant 81 (20) 81 (19)
Withdrew for other reasons 22 (6) 16 (4)
Had HIV seroconversion 27 (7) 27 (6)
Modified intention-to-treat analysis — person-yr of follow-up 607 680
Intention-to-treat analysis — person-yr of follow-up 699 777
On-treatment analysis — person-yr of follow-up 605 676
On-treatment analysis, according to level of adherence — person-yr of follow-up (%)*
≥90% 318 (52) 348 (51)
75 to <90% 97 (16) 126 (19)
<75% 90 (15) 89 (13)
Unknown 101 (15) 113 (17)
* Level of adherence was estimated on the basis of tablet count for each 3-month period of observation.
The New England Journal of Medicine 
Downloaded from nejm.org at LONDON SCH HYGIENE & TROPICAL MED on February 14, 2014. For personal use only. No other uses without permission. 
 Copyright © 2008 Massachusetts Medical Society. All rights reserved. 
Effect of HSV-2 Suppression on HIV Incidence
n engl j med 358;15 www.nejm.org ㄐㄐapril 10, 2008 1569
Table 3. Effect of Acyclovir Therapy on the Incidence of HIV Infection.
Analysis Acyclovir Group Placebo Group Rate Ratio (95% CI)
No. of HIV 
Seroconversions
HIV Infection Rate  
per 100 Person-Yr 
(95% CI)
No. of HIV 
Seroconversions
HIV Infection Rate 
per 100 Person-Yr 
(95% CI)
Modified intention-to-treat  
analysis
27 4.44 (3.0–6.5) 28 4.12 (2.8–6.0) 1.08 (0.64–1.83)
Intention-to-treat analysis 30 4.29 (3.0–6.1) 33 4.25 (3.0–6.0) 1.01 (0.61–1.66)
On-treatment analysis 27 4.46 (3.1–6.5) 27 4.00 (2.7–5.8) 1.12 (0.66–1.90)
On-treatment analysis, according 
to level of adherence*
≥90% 8 2.52 (1.3–5.0) 15 4.31 (2.6–7.2) 0.58 (0.25–1.38)
75 to <90% 5 5.17 (2.2–12.5) 6 4.76 (2.1–10.6) 1.09 (0.33–3.56)
<75% 5 5.57 (2.3–13.4) 2 2.24 (0.6–9.0) 2.48 (0.48–12.8)
Unknown 9 8.93 (4.6–17.2) 4 3.54 (0.1–9.4) 2.52 (0.78–8.19)
* Level of adherence was estimated on the basis of tablet count for each 3-month period of observation. Analyses attributed an HIV infection 
to the adherence category for the 3-month interval in which the infection occurred.
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Figure 2. Kaplan–Meier Estimates of the Cumulative Percentage of Patients 
with HIV Infection, According to Study Group.
a small number of participants in the placebo 
group are unlikely to have affected the overall 
outcome of the trial, given the drug’s short dura-
tion of action.
Despite the limitations of the trial, it is un-
likely that we have failed to detect a moderate or 
strong effect of acyclovir on HIV acquisition that 
would be important at the public health level. 
This trial underlines the challenges in asking 
asymptomatic individuals to take tablets to treat 
one virus (HSV-2) to prevent infection with or 
shedding of another virus (HIV). Improved ad-
herence at a level that might be required to dem-
onstrate an effect of acyclovir might be achieved 
by more frequent clinic visits, by the use of elec-
tronic monitoring devices that can record the 
time when a bottle of medication is opened,28,29 
or by working with a study population with 
greater access to health care services and there-
fore a better understanding of the importance of 
adherence.
The proportion of participants shedding HSV-
2 was low in both groups as compared with the 
proportions shedding in other recent studies in 
both HIV-negative and HIV-positive women in 
Africa.11,12,30,31 Recurrences of HSV-2 episodes 
are most frequent in the first months and years 
after primary infection.32,33 Many characteristics 
of our participants were similar to those of a 
Nairobi cohort in which HSV-2 was shown to be 
associated with increased numbers of genital 
mucosal target cells that may increase suscepti-
bility to HIV infection.23 However, it is possible 
that our participants had acquired HSV-2 early 
and had reached a stage at which their HSV-2 
infection was not active enough to contribute sub-
stantially to the risk of HIV acquisition. A recent 
meta-analysis demonstrated little overall associ-
ation between HSV-2 and the acquisition of HIV 
in high-risk women,8 and it is conceivable that 
other risk factors outweigh the influence of 
HSV-2 on the risk of HIV acquisition in such 
groups. Our trial was carried out in a population 
at moderately high risk for acquiring HIV. There-
fore, the results may not be applicable to women 
in the general population.
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The results of this trial indicate that, despite 
good biologic plausibility, acyclovir at a dose of 
400 mg twice daily is not a viable public health 
intervention for preventing infection with HIV. It 
is possible that the hypothesis that infection with 
HSV increases HIV acquisition is false, but this 
seems unlikely, given the strong biologic and epi-
demiologic evidence for a synergistic effect be-
tween HIV and HSV-2. The potential of HSV sup-
pression in HIV-positive subjects for preventing 
transmission of HIV will be tested in an ongoing 
multicenter trial among HIV-serodiscordant cou-
ples that is scheduled for completion in 2009. 
The lack of effect of suppressive therapy on HIV 
acquisition suggests that renewed attention should 
be given to new strategies of HSV-2 prevention 
and control to prevent HIV infection.
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